{"id":16389,"date":"2023-07-06T10:47:00","date_gmt":"2023-07-06T02:47:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16389"},"modified":"2024-12-03T11:01:30","modified_gmt":"2024-12-03T03:01:30","slug":"tot-biopharmaceutical-and-gl-biotech-collaborate-on-disaclink-technology-for-adc-advancements","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16389","title":{"rendered":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements"},"content":{"rendered":"\n

China-based Tot Biopharma International Co., Ltd (HKG: 1875<\/a>) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech’s proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.<\/p>\n\n\n\n

Enhancing ADC Homogeneity and Stability with DisacLink Technology<\/strong>
Traditional antibody drug conjugates (ADCs) face challenges with poor homogeneity and low stability due to the use of the amino group of antibody lysine or the sulfhydryl group of cysteine obtained by opening the disulfide bond between chains for coupling. This affects the efficacy and treatment window of ADCs. To address these issues, researchers have developed a site-specific coupling method using cysteine, glutamine, unnatural amino acids, short peptide tags, and polysaccharides. This method allows for the coupling of cytotoxic or chemotherapy drugs to specific locations within the antibody molecule, resulting in ADCs with high uniformity, good stability, better activity, and improved pharmacokinetic characteristics.<\/p>\n\n\n\n

GL-Biotech’s Focus on Fixed ADC Drug Development<\/strong>
Founded in 2021, GL-Bio is dedicated to the research and development of fixed ADC drugs, with a focus on the oncology field. The company’s commitment to innovation in ADC technology positions it at the forefront of cancer treatment advancements.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,19,1894,2571],"class_list":["post-16389","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-cro-cmo-cdmo","tag-hkg-1875","tag-tot-biopharm"],"yoast_head":"\nTot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech's proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16389\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16389\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-06T02:47:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T03:01:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements\",\"datePublished\":\"2023-07-06T02:47:00+00:00\",\"dateModified\":\"2024-12-03T03:01:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"CRO \\\/ CMO \\\/ CDMO\",\"HKG: 1875\",\"Tot Biopharm\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16389#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16389\",\"name\":\"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-06T02:47:00+00:00\",\"dateModified\":\"2024-12-03T03:01:30+00:00\",\"description\":\"China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech's proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16389\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16389#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements - Insight, China's Pharmaceutical Industry","description":"China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech's proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16389","og_locale":"en_US","og_type":"article","og_title":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16389","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-06T02:47:00+00:00","article_modified_time":"2024-12-03T03:01:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16389#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16389"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements","datePublished":"2023-07-06T02:47:00+00:00","dateModified":"2024-12-03T03:01:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16389"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","CRO \/ CMO \/ CDMO","HKG: 1875","Tot Biopharm"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16389#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16389","url":"https:\/\/flcube.com\/?p=16389","name":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-06T02:47:00+00:00","dateModified":"2024-12-03T03:01:30+00:00","description":"China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech's proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16389#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16389"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16389#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16389"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16389\/revisions"}],"predecessor-version":[{"id":16393,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16389\/revisions\/16393"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}